Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Cash from Operations (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Cash from Operations for 6 consecutive years, with 658247.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 43.4% year-over-year to 658247.0, compared with a TTM value of 2717961.0 through Sep 2025, up 7.44%, and an annual FY2024 reading of 2817478.0, up 31.52% over the prior year.
  • Cash from Operations was 658247.0 for Q3 2025 at Xenetic Biosciences, down from 383830.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 383830.0 in Q2 2025 and bottomed at 1269120.0 in Q2 2023.
  • Average Cash from Operations over 3 years is 815969.64, with a median of 793027.0 recorded in 2023.
  • The sharpest move saw Cash from Operations skyrocketed 58.62% in 2024, then crashed 43.4% in 2025.
  • Year by year, Cash from Operations stood at 793027.0 in 2023, then grew by 15.01% to 673992.0 in 2024, then increased by 2.34% to 658247.0 in 2025.
  • Business Quant data shows Cash from Operations for XBIO at 658247.0 in Q3 2025, 383830.0 in Q2 2025, and 1001892.0 in Q1 2025.